Neutrophil‐Based Delivery Systems for Nanotherapeutics

Abstract Neutrophils, the most abundant leukocytes (50–70% of the total leukocytes in circulation), are the major type of cells recruited to sites of inflammation during infection and tumorigenesis, suggesting that neutrophils could contribute to nanotherapeutics for inflammation and cancer therapy. Neutrophil‐based delivery has shown great potential in circumventing nanotherapeutics limitations, such as low biocompatibility, short circulation time, and immunogenicity of nanomaterials. In this review, the current development of neutrophil‐based nanotherapeutic drugs in the treatment of inflammatory diseases and cancers is summarized. These successful neutrophil‐based nanotherapeutic systems indicate that introducing functional nanomaterials into neutrophils and neutrophil‐based vesicles may be a promising strategy for improving the nanotherapeutics in more complex conditions. The integration between neutrophils and nanomaterials will create more opportunities for future materials and medical studies.